Revance Therapeutics Inc (RVNC) - מקדם חוב לטווח ארוך להון

The rapid surge in Daxxify adoption within the aesthetics sector provides Revance Therapeutics (RVNC) with significant momentum, while the 0.00 metric of the stock price tracked on the chart helps monitor this trend. The business relies on a closed B2B environment that ties clinics to the brand's consumables. Protection against competitors is ensured by patents for prolonged effects and unique toxin purification methods, guaranteeing high physician loyalty.

This indicator is calculated as the ratio of liabilities with a maturity of over one year to the company's market capitalization. The metric determines the extent of the business's dependence on external long-term financing relative to investors' equity. For Revance Therapeutics (RVNC), this reflects the cost of owning an automated plant in California and the independence of production. The current value of 0.00 characterizes the level of financial leverage. By analyzing the dynamics of the long-term debt-to-equity ratio, one can assess the sustainability of the scaling model.